OMass Therapeutics: Board Welcomes Birgitte Volck

OMass Therapeutics, a biotechnology company based in Oxford, UK, has announced the appointment of Dr. Birgitte Volck as a Non-Executive Director. Dr. Volck brings over 25 years of industry experience, especially in rare diseases and precision medicine. Her track record includes key roles at Ascendis Pharma and GSK, among others. OMass specializes in creating medicines targeting validated ecosystems of membrane proteins and intracellular complexes. Leveraging its unique drug discovery platform, OMass is advancing therapeutics for rare diseases and immunological conditions. The company's lead program aims to treat Congenital Adrenal Hyperplasia and Cushing's Syndrome by developing small molecule therapeutics that resist competition from endogenous ligands. OMass has raised over $160 million from prominent investors and plans to leverage Dr. Volck's expertise to strengthen its strategic growth into a clinical-stage company.